Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV) Vaccine

5 novembre 2026 mis à jour par: Serum Institute of India Pvt. Ltd.

A Phase 1/2, Double-blinded, Randomised, Active Controlled, Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV) Vaccine in Comparison With Gardasil 9 Vaccine in Healthy Adults

Human papilloma virus (HPV) is the most common viral infection of the reproductive system and is spread through contact with infected genital skin, mucous membranes, or bodily fluids. This study will assess an experimental vaccine called 10 valent Human Papillomavirus Virus (10vHPV) for the safety, reactivity, and immune response, in healthy adults, compared to Gardasil 9.

There are two phases in this study - Phase 1 will include up to 36 healthy adults aged 18-25 years, Phase 2 will include 36 healthy adults aged 26-45 years. Participants will be randomised in a 2-to-1 ratio to receive either 10vHPV or Gardasil 9.

10vHPV or Gardasil 9 will be administered as a 0.5 mL single dose via intramuscular injection in the deltoid muscle of the upper arm. In Phase 1, participants will receive a single dose on Day 1, and in Phase 2, participants will receive a single dose on Day 1, 2 months, and 6 months.

Aperçu de l'étude

Statut

Pas encore de recrutement

Type d'étude

Interventionnel

Inscription (Estimé)

72

Phase

  • Phase 2
  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • Victoria
      • East Melbourne, Victoria, Australie, 3002
        • Doherty Clinical Trials Limited
        • Contact:
        • Chercheur principal:
          • James Molton

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 45 ans (Adulte)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Males and females aged 18 to 25 years inclusive at Screening (Phase 1 Only)
  • Males and females aged 26 to 45 years inclusive at Screening (Phase 2 Only)
  • Willing and able to sign an Informed Consent Form (ICF)
  • Good physical and mental health based on medical history, physical examination, clinical laboratory, electrocardiogram (ECG), and vital signs, as judged by the Investigator
  • Participants willing and able to comply with the requirements of the Protocol
  • Participants agree to refrain from strenuous exercise (including weightlifting) within 96 hours (4 days) prior to Screening, and each day of vaccine administration
  • Willing and able to comply with restrictions of nicotine use throughout the study is not permitted from within 48 hours [2days] prior to Screening, from Day 1 until Day 8, and within 48 hours [2 days] prior to the end of study [EoS/early termination [ET} visit)
  • Male participants, if not surgically sterilised or have partners of the same sex, must agree to use highly effective contraception and not plan a pregnancy or donate sperm from Day 1 until 90 days after the last study visit.
  • Female participants of childbearing potential who have fertile male sexual partners must agree to use highly effective contraception from Day 1 until 90 days after the last study visit.

Exclusion Criteria:

  • Positive drug and/or alcohol screen at Screening and Day 1 (Phase 1 Only)
  • Are vaccinated against HPV
  • History of HPV infection and associated medical conditions (confirmed either clinically, serologically, or microbiologically) including history of abnormal Papanicolau test, HPV DNA test, abnormal cervical biopsy,or external genital warts, as reported by the participant
  • History of administration of any investigational or non-registered product (drug or vaccine) 30 days prior to study vaccine administration on Day 1 or plan to participate in another study with investigational drug or vaccine prior to Day 30
  • Any vaccination received 30 days before Screening or plan to receive a vaccination between Screening and Day 30
  • Pregnant or lactating females or females planning to become pregnant or beast feed during the study
  • Any findings on medical examination deviating from normal and assessed as clinically relevant by the investigator
  • A participant who has a body mass index (BMI) >35.0 kg/m2
  • A participant who has skin markings in both deltoid areas, which prevents injection site reaction (ISR)assessment, in the opinion of the investigator
  • History of alcohol abuse or drug addiction
  • Positive screen for HBsAg, HBcAb, HCV antibodies, or HIV 1 and 2 antibodies
  • History of a severe allergic reaction (e.g. anaphylaxis) after any vaccine or to any component (active substances or excipients) of the study vaccines
  • History of major congenital defects or developmental disorders or genetic diseases as determined by medical history or clinical assessment
  • History of thrombocytopenia or a bleeding disorder following an IM injection
  • History or current evidence of any condition or therapy which might interfere with the participant's participation for the full duration of the study, evidence of suspected diseases, or is not in the best interest of the participants to participate, in the opinion of the investigator
  • History of major surgery =30 days prior to study vaccination on Day 1. If the participant has had any surgery >30 days prior to the study vaccination on Day 1, the participant can be enrolled in the study at the discretion of the investigator
  • Acute illness (moderate or severe) and/or fever (tympanic) (temperature ≥38.0°C) at the time of vaccination or during the 72 hours prior to the vaccination on Visit 2 (Day 1) should be delayed until the participant is fully recovered and fever-free
  • History of receipt of a blood transfusion, other blood products, or immunoglobulins in 3 months prior to study vaccination, or planned receipt of blood products during the study period.
  • Any confirmed or suspected congenital or acquired immunosuppressive, immunodeficient condition or autoimmune disease, based on medical history and physical examination.
  • Family history of any medical conditions, that in the Investigator's opinion, could affect the trial outcomes.
  • Chronic administration (defined as >14 days) of immunosuppressant or other immune modifying drugs(including topical calcineurin inhibitors) during the period starting 6 months prior to the study vaccine administration or planned during the study period up to Visit 4 (Day 30 [-2 to +14 days]).
  • Any plans to permanently relocate from the area prior to the completion of the study or to leave for an extended period of time when study visits would be scheduled.
  • Employee of any organisation associated with this study.
  • History of clinically relevant drug and/or food allergies.
  • History of alcohol consumption of more than 10 standard drinks/week and no more than 4 standard drinks on any one day within 3 months prior to Screening.
  • Any physical, psychological, mental and/or social reason which in the opinion of the Investigator makes the participant unsuitable for the study.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: 10vHPV Vaccine

10vHPV is manufactured by Serum Institute of India Pvt. Ltd and is a 10-valent recombinant VLP vaccine containing the major capsid (L1) protein

Comparateur actif: Gardasil9

Gardasil9 is manufactured by Merck Sharp & Dohme (MSD) and is a 9-valent recombinant VLP vaccine containing the major capsid (L1) protein

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
To assess the safety and reactogenicity of a single dose of 10vHPV vaccine in comparison with a single dose of Gardasil 9 vaccine in healthy adults aged 18 to 25 years in phase 1.
Délai: 30 days after vaccination

The incidence, severity and relationship of solicited AEs during 7-day, unsolicited and serious adverse events during 30-day follow-up period after administration of a single dose.

30 days after vaccination
To assess the safety of 3 doses (administered at day 0, 60 and 180) of 10vHPV vaccine in comparison with 3 doses (administered at day 0, 60 and 180) of Gardasil 9 vaccine in healthy adults aged 26 to 45 years.
Délai: 30 days after last dose

The incidence, severity and relationship of solicited AEs during 7-day after each vaccine dose, unsolicited and serious adverse events up to 30 days after the last dose .

30 days after last dose

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
To assess immune response 30 days after vaccination with 10vHPV vaccine compared to Gardasil 9 in healthy adults aged 18 to 25 years.
Délai: 30 days after vaccination

Percentage of participants achieving seroconversion, Geometric mean titres (GMTs) for anti-HPV antibodies, Geometric mean fold rise (GMFR) on Day 30.

30 days after vaccination
To assess immune response 30 days after 3rd vaccination with 10vHPV vaccine compared to Gardasil 9 in healthy adults aged 26 to 45 years.
Délai: 7 months

Percentage of participants achieving seroconversion, GMTs for anti-HPV antibodies and GMFR on Day 30 post 3rd dose (Month 7)

7 months

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
To assess immune response 6 months after vaccination with 10vHPV vaccine compared to Gardasil 9 in healthy adults aged 18 to 25 years.
Délai: 6 month

Percentage of participants achieving seroconversion, GMTs for anti-HPV antibodies, GMFR at Month 6

6 month

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Directeur d'études: Hitt Sharma, Serum Institute of India Pvt. Ltd.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 novembre 2026

Achèvement primaire (Estimé)

1 février 2028

Achèvement de l'étude (Estimé)

1 avril 2028

Dates d'inscription aux études

Première soumission

26 septembre 2026

Première soumission répondant aux critères de contrôle qualité

15 octobre 2026

Première publication (Réel)

22 octobre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

6 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

5 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

Summary Results

Délai de partage IPD

24 month after the study completion

Critères d'accès au partage IPD

Researchers who provide a methodologically sound proposal may be provided the access afterSponsor permission and if signed data-access agreements are in place.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner